Genmab terminates Phase 1/2 GEN1055 trial for strategic reasons; results now posted
Genmab stopped its first-in-human GEN1055 study early and has posted results after 21 participants were enrolled.
This week's update covers one Genmab-sponsored trial that closed out with results posted after early termination.
- "Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy" (NCT06391775) is a Phase 1/2 study of GEN1055, alone or with pembrolizumab and chemotherapy, in malignant solid tumors. The trial's overall status is terminated, with the reason given as a strategic decision.1 Primary completion was recorded as 2025-11-20, and results were first posted on 2026-08-11.1 Enrollment reached 21 participants (actual).1 The study was sponsored by Genmab with BioNTech SE as a collaborator.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.